SCHEMBL3948651

SCHEMBL3948651

CC(=O)Nc1nc2c(s1)C(=O)C(C(=O)C1CC1)CC2

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 1/20 0.40
PI4KB Q9UBF8 3/20 0.36
AHR P35869 1/20 0.36
PIK3CG P48736 4/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
TP53 P04637 2/20 0.35
POLB P06746 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 1/20 0.34
DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4046327 0.95 NPC1 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4042563 0.95 ALDH1A1 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2143829 0.88 MAPT (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4512392 0.85 MAPT (0.40) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2143750 0.84 LMNA (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL14365582 0.83 ALDH1A1 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2143795 0.83 SMN1; SMN2 (0.52) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2143873 0.83 SMN1; SMN2 (0.52) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2143793 0.83 SMN1; SMN2 (0.52) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2143880 0.83 SMN1; SMN2 (0.52) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101466717-A Thiazolyldihydroindazoles BOEHRINGER INGELHEIM INT (DE) 2009-06-24 CN disclosed
US-20090093474-A1 THIAZOLYL-DIHYDRO-INDAZOLE GRAUERT MATTHIAS 2009-04-09 US disclosed
US-20090093474-A1 THIAZOLYL-DIHYDRO-INDAZOLE GRAUERT MATTHIAS 2009-04-09 US disclosed
US-20090093474-A1 THIAZOLYL-DIHYDRO-INDAZOLE GRAUERT MATTHIAS 2009-04-09 US disclosed
EP-2018387-A1 THIAZOLYLDIHYDROINDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-01-28 EP disclosed
WO-2007115933-A1 THIAZOLYLDIHYDROINDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
WO-2007115933-A1 THIAZOLYLDIHYDROINDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-18 WO disclosed
US-20070238718-A1 THIAZOLYL-DIHYDRO-INDAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070238718-A1 THIAZOLYL-DIHYDRO-INDAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed
US-20070238718-A1 THIAZOLYL-DIHYDRO-INDAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093474-A1 THIAZOLYL-DIHYDRO-INDAZOLE CYP3A43, CYP3A5, UGT1A3 ALDH1A1 162/4885NPC1 1007/4885RAB9A 2050/4885
US-20070238718-A1 THIAZOLYL-DIHYDRO-INDAZOLE CYP3A43, CYP3A5, UGT1A3 ALDH1A1 162/4885NPC1 1007/4885RAB9A 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.